Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/I9DN stock hub

FRA/I9DN has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/I9DNis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

726.2M

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/I9DNFRA/I9DN

—

Loading chart…

In the news

Latest news · FRA/I9DN

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-38.5

P25 n/aP50 n/aP75 n/a

ROIC-18.4

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/I9DN market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

156

Groups with data

Currency

USD

Showing 156 of 156 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Canada
Country code	DE
Employees	19
Employees Change	-29%
Employees Change Percent	-39.73
Enterprise value	EUR 652M
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 726.2M
Price	EUR 3.64
Price currency	EUR
Rev Per Employee	631,289x
Sic	2836
Symbol	fra/I9DN
Website	https://www.arbutusbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-3.93%
EV Earnings	-22.85x
EV/Sales	54.49x
P/B ratio	11.13x
P/S ratio	60.54x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-192.08%
EBITDA Margin	-189.51%
Gross margin	-79.23%
Gross Profit	EUR -9.5M
Net Income	EUR -28.5M
Pretax Margin	-237.88%
Profit Margin	-237.88%
Profit Per Employee	EUR -1.5M
ROA	-14.94
Roa5y	-24.26
ROCE	-30.53
ROE	-38.52
Roe5y	-53.76
ROIC	-18.35

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-0.53%
Cagr1y	26.67%
Cagr3y	16.87%
Cagr5y	8.88%
Revenue Growth	128.21x
Revenue Growth Q	-33.23x
Revenue Growth3 Y	-28.8x
Revenue Growth5 Y	15.29x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.12
Assets	EUR 80.6M
Cash	EUR 77.9M
Current Assets	EUR 80.1M
Current Liabilities	EUR 5.1M
Debt	EUR 3.6M
Debt Equity	EUR 0.05
Equity	EUR 65.2M
Interest Coverage	-278.9
Liabilities	EUR 15.4M
Long Term Assets	EUR 491,052
Long Term Liabilities	EUR 10.3M
Net Cash	EUR 74.3M
Net Cash By Market Cap	EUR 10.24
Net Cash Growth	-25.08%
Net Debt Equity	EUR -1.14
Tangible Book Value	EUR 65.2M
Tangible Book Value Per Share	EUR 0.34

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	15.73
Net Working Capital	EUR -2.1M
Quick ratio	15.52
Working Capital	EUR 75.3M
Working Capital Turnover	EUR 0.12

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-3.23%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-5.13%
1Y total return	26.65%
200-day SMA	3.59
3Y total return	59.65%
50-day SMA	3.77
50-day SMA vs 200-day SMA	50over200
5Y total return	53.01%
All Time High	23.8
All Time High Change	-84.71%
All Time High Date	2014-10-06
All Time Low	0.77
All Time Low Change	375.32%
All Time Low Date	2019-10-31
ATR	0.08
Ch YTD	-7.19
High	3.65
High52	4.31
High52 Date	2025-09-11
High52ch	-15.55%
Low	3.64
Low52	2.56
Low52 Date	2025-07-01
Low52ch	42.19%
Ma50ch	-3.32%
Price vs 200-day SMA	1.36%
RSI	47.48
RSI Monthly	55.34
RSI Weekly	50.22
Sharpe ratio	0.65x
Sortino ratio	1.12
Total Return	-3.23%
Tr YTD	-7.19
Tr1m	-4.21%
Tr1w	0.28%
Tr3m	19.9%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR -23M
Operating margin	-192.1

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	126,693,713%
Shares Insiders	1.53%
Shares Institutions	49.97%
Shares Qo Q	0.3%
Shares Yo Y	3.23%
Short Ratio	7.92

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	75x
Bv Per Share	0.34
Ch10y	-5.13
Ch1m	-4.21
Ch1w	0.28
Ch1y	26.65
Ch3m	19.9
Ch3y	59.65
Ch5y	53.01
Ch6m	-3.45
Change	-1.62%
Change From Open	-0.27
Close	3.7
Days Gap	-1.35
Depreciation Amortization	307,810.2
Earnings Date	2026-05-14
EBIT	EUR -23M
EBITDA	EUR -22.7M
EPS	EUR -0.15
F Score	4
Financing CF	4,872,576
Fiscal Year End	December
Founded	2,005
Investing CF	13,269,486
Is Primary Listing	0
Last Report Date	2025-12-31
Ma150	3.72
Ma150ch	-2.23%
Ma20	3.68
Ma20ch	-0.95%
Net CF	-15,604,847
Next Earnings Date	2026-05-14
Open	3.65
Position In Range	0
Ppne	27,134.8
Price Date	2026-05-08
Ptbv Ratio	11.13
Relative Volume	1.33x
Revenue	11,994,491x
SBC By Revenue	49.37x
Share Based Comp	5,921,870
Tr6m	-3.45%
Volume	0
Z Score	3.54

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/I9DN pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/I9DN stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/I9DN?

Insider, institutional, and short-interest positioning.

Institutional ownership

+50.0%

Share of float held by funds and institutions

Insider ownership

+1.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

FRA/I9DN momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

47.5

Neutral momentum band

Price vs 200-day MA

+1.4%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.65

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/I9DN

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/I9DN stock rating?

fra/I9DN is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/I9DN analysis?

The full report lives at /stocks/fra/I9DN/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/I9DN?

The latest report frames fra/I9DN around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/I9DN page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.